ArticleMolecular medicine (Cambridge, Mass.)2026
The post-transcriptional regulatory RNA-binding protein PTBP1 functions as an inhibitor in hepatic stellate cell activation and liver fibrosis.
Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundHepatic stellate cell (HSC) activation is the key step in liver fibrogenesis characterized by excessive extracellular matrix (ECM) accumulation, which is based on fibrogenic factors-induced changes in gene expression in HSCs. The post-transcriptional gene-expression regulation plays a crucial role in regulation of gene expression by controlling mRNA fate through RNA binding proteins (RBPs), RBPs are essentially involved in the process of HSC activation and liver fibrogenesis. Since the activated HSCs possess the characteristics of neuron and the roles of multifunctional polypyrimidine tract binding protein 1 (PTBP1), a key RBP in inhibiting neuron differentiation, in HSC activation and liver fibrosis are elusive, this research aimed to investigate the effects of PTBP1 on HSC activation and liver fibrosis.
methodsThe study employed RNA sequencing, targeted over-expression of Ptbp1, Ptbp1 gene-knockdown mice, different mouse model of liver fibrosis, and liver samples from clinical patients.
resultsPtbp1 silencing in HSCs in vitro led to an increase in the expression of many pro-fibrotic genes, including at least the most potent fibrogenic factors, fibrogenic factor receptors, signal transducer, and ECM, but caused a decrease in the expression of pro-apoptotic genes and transcriptional factor Srebp1c, a key one to inhibiting HSC activation. Ptbp1 knockdown in mouse upregulated the expression of pro-fibrotic genes and enhanced HSC activation as well as liver fibrosis. Targeted over-expression of Ptbp1 in HSCs in the model of liver fibrosis further confirmed the effects of PTBP1 on the pro- and anti-fibrotic gene expression in HSCs, HSC activation, and liver fibrosis. Ptbp1 could bind to Srebp1c mRNA, thus inhibiting its degradation. PTBP1 also blocked PI3K/Akt pathway in HSCs. Its levels were reduced in the activated HSCs in livers from mice and clinical patients.
conclusionThis research demonstrated a previously unrecognized inhibitory effect of the multifunctional PTBP1 on HSC activation and liver fibrogenesis and the underlying mechanisms were involved in PTBP1 regulation of the important pro- or anti-fibrotic genes. Given that PTBP1 targeted lots of important pro- and anti-fibrotic genes, PTBP1 may serve as a potential therapeutic strategy for treatment of liver fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.